CL2007003807A1 - Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado - Google Patents
Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediadoInfo
- Publication number
- CL2007003807A1 CL2007003807A1 CL200703807A CL2007003807A CL2007003807A1 CL 2007003807 A1 CL2007003807 A1 CL 2007003807A1 CL 200703807 A CL200703807 A CL 200703807A CL 2007003807 A CL2007003807 A CL 2007003807A CL 2007003807 A1 CL2007003807 A1 CL 2007003807A1
- Authority
- CL
- Chile
- Prior art keywords
- understands
- symptoms
- fragments
- treat
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87610906P | 2006-12-21 | 2006-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007003807A1 true CL2007003807A1 (es) | 2008-05-09 |
Family
ID=39563077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200703807A CL2007003807A1 (es) | 2006-12-21 | 2007-12-21 | Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100092484A1 (es) |
EP (1) | EP2102238A4 (es) |
JP (1) | JP2010512790A (es) |
KR (1) | KR20090094848A (es) |
CN (1) | CN101605812A (es) |
AR (1) | AR064456A1 (es) |
AU (1) | AU2007338844A1 (es) |
BR (1) | BRPI0720477A2 (es) |
CA (1) | CA2672916A1 (es) |
CL (1) | CL2007003807A1 (es) |
MX (1) | MX2009006891A (es) |
PE (1) | PE20081478A1 (es) |
RU (1) | RU2009128064A (es) |
TW (1) | TW200846365A (es) |
UY (1) | UY30776A1 (es) |
WO (1) | WO2008079246A2 (es) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8231872B2 (en) * | 2005-04-25 | 2012-07-31 | The Trustees Of Dartmouth College | Regulatory T cell mediator proteins and uses thereof |
US8313914B2 (en) * | 2009-03-06 | 2012-11-20 | Angstrom Pharmaceuticals, Inc. | Compositions and methods for modulation of cell migration |
US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
WO2012142238A2 (en) * | 2011-04-12 | 2012-10-18 | Duke University | Compositions and methods for the treatment of tissue fibrosis |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
JP2015527869A (ja) | 2011-08-26 | 2015-09-24 | メリマック ファーマシューティカルズ インコーポレーティッド | タンデムFc二重特異性抗体 |
EP2788024A1 (en) * | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
EP2814829B1 (en) | 2012-02-13 | 2016-12-07 | Bristol-Myers Squibb Company | Enediyne compounds, conjugates thereof, and uses and methods therefor |
KR102215954B1 (ko) | 2013-02-14 | 2021-02-15 | 브리스톨-마이어스 스큅 컴퍼니 | 튜부리신 화합물, 그의 제조 및 사용 방법 |
EA201591652A1 (ru) | 2013-03-06 | 2016-02-29 | Мерримак Фармасьютикалз, Инк. | ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET |
CN103288958B (zh) * | 2013-03-22 | 2015-03-04 | 暨南大学 | 抗癌症干细胞特异性蛋白cd44的单链抗体及其应用 |
JP6474404B2 (ja) | 2013-08-14 | 2019-02-27 | ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 |
NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
EP3080161B1 (en) | 2013-12-09 | 2021-03-24 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
US20170240631A1 (en) | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
ES2747386T3 (es) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
MA53108A (fr) | 2015-01-26 | 2021-05-12 | Lubris Llc | Utilisation de prg4 comme agent anti-inflammatoire |
CA2981851A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
CN116063499A (zh) | 2015-06-12 | 2023-05-05 | 艾利妥 | 抗cd33抗体及其使用方法 |
CN115960235A (zh) | 2015-08-28 | 2023-04-14 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
JP2018537956A (ja) | 2015-10-06 | 2018-12-27 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
CA3003458A1 (en) | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
WO2017112624A1 (en) | 2015-12-21 | 2017-06-29 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
JP7023853B2 (ja) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗trem1抗体及びその使用方法 |
WO2017196598A1 (en) | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugates of tubulysin analogs with enhanced stability |
KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
EP3630833A1 (en) | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
PT3601358T (pt) | 2017-08-03 | 2023-08-30 | Alector Llc | Anticorpos anti-trem2 e métodos de uso dos mesmos |
BR112019023789A2 (pt) | 2017-08-03 | 2020-07-28 | Alector Llc | anticorpos anti-cd33 e métodos de uso dos mesmos |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
CN111886246A (zh) | 2017-12-29 | 2020-11-03 | 艾莱克特有限责任公司 | 抗tmem106b抗体及其使用方法 |
EP3746476A1 (en) | 2018-01-31 | 2020-12-09 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
WO2019226973A1 (en) | 2018-05-25 | 2019-11-28 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
CN112188902A (zh) | 2018-05-29 | 2021-01-05 | 百时美施贵宝公司 | 用于前药和缀合物的经修饰的自消灭部分以及使用和制造方法 |
EP3801767A1 (en) | 2018-06-08 | 2021-04-14 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
JP2021529520A (ja) | 2018-06-29 | 2021-11-04 | アレクトル エルエルシー | 抗sirp−ベータ1抗体及びその使用方法 |
MX2021000009A (es) * | 2018-07-09 | 2021-03-09 | Five Prime Therapeutics Inc | Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4). |
BR112019022666A2 (pt) | 2018-07-13 | 2020-09-01 | Alector Llc | anticorpos antissortilina e métodos de uso dos mesmos |
EA202190183A1 (ru) | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
MX2021002299A (es) | 2018-08-31 | 2021-04-28 | Alector Llc | Anticuerpos de anti-cd33 y metodos para usarlos. |
JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル-マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
AU2019386945A1 (en) | 2018-11-30 | 2021-07-22 | Bristol-Myers Squibb Company | Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses |
WO2020123425A2 (en) | 2018-12-12 | 2020-06-18 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
KR102259298B1 (ko) * | 2019-05-15 | 2021-05-31 | 강원대학교 산학협력단 | 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용 |
AU2020291527A1 (en) | 2019-06-11 | 2022-01-20 | Alector Llc | Anti-Sortilin antibodies for use in therapy |
BR112022001733A2 (pt) | 2019-07-31 | 2022-06-28 | Alector Llc | Anticorpos anti-ms4a4a e métodos de uso dos mesmos |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
KR20220110537A (ko) | 2019-12-05 | 2022-08-08 | 알렉터 엘엘씨 | 항-trem2 항체 사용 방법 |
AU2020403021A1 (en) | 2019-12-12 | 2022-06-23 | Alector Llc | Methods of use of anti-CD33 antibodies |
MX2022007231A (es) | 2019-12-13 | 2022-07-12 | Alector Llc | Anticuerpos anti-mertk y metodos de uso de los mismos. |
WO2021173565A1 (en) | 2020-02-24 | 2021-09-02 | Alector Llc | Methods of use of anti-trem2 antibodies |
CN116075525A (zh) | 2020-03-31 | 2023-05-05 | 艾莱克特有限责任公司 | 抗mertk抗体及其使用方法 |
CA3172451A1 (en) | 2020-04-03 | 2021-10-07 | Robert Paul | Methods of use of anti-trem2 antibodies |
JP2023526529A (ja) | 2020-05-19 | 2023-06-21 | アンスティテュ・クリー | サイトカイン放出症候群の診断及び処置の方法 |
CN114057874B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途 |
US20240101681A1 (en) | 2020-12-02 | 2024-03-28 | Alector Llc | Methods of use of anti-sortilin antibodies |
EP4308606A1 (en) | 2021-03-18 | 2024-01-24 | Alector LLC | Anti-tmem106b antibodies and methods of use thereof |
EP4314063A1 (en) | 2021-03-23 | 2024-02-07 | Alector LLC | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
BR112023024209A2 (pt) | 2021-05-18 | 2024-01-30 | Janssen Biotech Inc | Composições que compreendem um agente terapêutico de redirecionamento de células t e um agente terapêutico anti-cd44 |
EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
CN116496398B (zh) * | 2022-10-31 | 2023-10-31 | 南京元迈细胞生物科技有限公司 | 一种特异性结合CD44的v5外显子的抗体及其用途 |
CN116554300B (zh) * | 2023-04-27 | 2023-10-24 | 湖北医药学院 | 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5543594A (en) * | 1992-10-30 | 1994-05-24 | Duke University | An adhesion molecule |
US6001356A (en) * | 1995-09-29 | 1999-12-14 | Rush-Presbyterian-St. Luke's Medical Center | Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies |
US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
AU2001292943A1 (en) * | 2000-09-21 | 2002-04-02 | The Brigham And Women's Hospital, Inc. | Prevention and treatment of streptococcal and staphylococcal infection |
US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
EP1532984A1 (en) * | 2003-11-19 | 2005-05-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia |
CA2560200A1 (en) * | 2004-03-17 | 2005-09-22 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Cd44-targeting for reducing/preventing ischemia-reperfusion-injury |
-
2007
- 2007-12-10 UY UY30776A patent/UY30776A1/es not_active Application Discontinuation
- 2007-12-12 PE PE2007001771A patent/PE20081478A1/es not_active Application Discontinuation
- 2007-12-14 TW TW096148114A patent/TW200846365A/zh unknown
- 2007-12-19 AR ARP070105733A patent/AR064456A1/es unknown
- 2007-12-20 US US12/518,856 patent/US20100092484A1/en not_active Abandoned
- 2007-12-20 BR BRPI0720477-9A2A patent/BRPI0720477A2/pt not_active Application Discontinuation
- 2007-12-20 EP EP07863135A patent/EP2102238A4/en not_active Withdrawn
- 2007-12-20 AU AU2007338844A patent/AU2007338844A1/en not_active Abandoned
- 2007-12-20 JP JP2009542902A patent/JP2010512790A/ja active Pending
- 2007-12-20 RU RU2009128064/10A patent/RU2009128064A/ru not_active Application Discontinuation
- 2007-12-20 KR KR1020097015180A patent/KR20090094848A/ko not_active Application Discontinuation
- 2007-12-20 CA CA002672916A patent/CA2672916A1/en not_active Abandoned
- 2007-12-20 MX MX2009006891A patent/MX2009006891A/es not_active Application Discontinuation
- 2007-12-20 WO PCT/US2007/025975 patent/WO2008079246A2/en active Application Filing
- 2007-12-20 CN CNA200780050041XA patent/CN101605812A/zh active Pending
- 2007-12-21 CL CL200703807A patent/CL2007003807A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010512790A (ja) | 2010-04-30 |
KR20090094848A (ko) | 2009-09-08 |
TW200846365A (en) | 2008-12-01 |
AR064456A1 (es) | 2009-04-01 |
CN101605812A (zh) | 2009-12-16 |
MX2009006891A (es) | 2009-08-28 |
UY30776A1 (es) | 2008-07-03 |
WO2008079246A2 (en) | 2008-07-03 |
PE20081478A1 (es) | 2008-12-07 |
AU2007338844A1 (en) | 2008-07-03 |
EP2102238A2 (en) | 2009-09-23 |
RU2009128064A (ru) | 2011-01-27 |
WO2008079246A3 (en) | 2009-01-08 |
BRPI0720477A2 (pt) | 2014-01-14 |
US20100092484A1 (en) | 2010-04-15 |
EP2102238A4 (en) | 2010-09-01 |
CA2672916A1 (en) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003807A1 (es) | Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado | |
CL2008000935A1 (es) | Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige. | |
CL2008000839A1 (es) | Anticuerpo anti-ige/m1'; acido nucleico que lo codifica; vector y celula huesped; proceso de produccion; composicion que comprende al anticuerpo; y su uso para tratar trastornos mediados por ige. | |
CL2008000578A1 (es) | Anticuerpo antagonista aislado anti-receptor ox40 humano; molecula de acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; su uso para tratar trastornos mediados por ox40; y metodo para detectar | |
CL2015000148A1 (es) | Inmunoglobulina g variante porque comprende dos o mas sustituciones de aminoácidos; composición farmacéutica y kit que comprenden dicha inmunolobulina; uso de dicha inmunoglobulina para tratar tumor | |
CL2007002070A1 (es) | Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade | |
CL2007003161A1 (es) | Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como | |
CL2007002987A1 (es) | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3. | |
BRPI0818677A2 (pt) | Anticorpos que se ligam à il-4 e/ou il-13, composições farmacêuticas compreendendo os referidos anticorpos, bem como usos dos mesmos | |
CL2007001488A1 (es) | Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina. | |
CL2009001424A1 (es) | Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso. | |
CL2007003623A1 (es) | Proteina de enlace multivalente monocatenaria con funcion efectora; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y metodo para tratar trastornos proliferativos. | |
BRPI0911060A2 (pt) | polipeptídeos de fator vii que são modificados e usos dos mesmos | |
CL2007002791A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri | |
CL2013002062A1 (es) | Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende: metodo de preparacion; y su uso para estimular la respuesta inmune. | |
CL2008000703A1 (es) | Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos. | |
CL2007002668A1 (es) | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. | |
CL2008001334A1 (es) | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. | |
CL2008000887A1 (es) | Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de | |
CL2007003212A1 (es) | Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
CL2007002989A1 (es) | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3. | |
CL2008001129A1 (es) | Variente de asparraginasa; secuencia de acido nucleico que la codifica; construccion de acidos nucleicos; vector y celula huesped; metodo para producir asparraginasa; composicion que comprende la variante; uso de la variante de asparraginasa; proceso | |
AR078516A1 (es) | Moleculas de union a dll-4 (ligando 4 de tipo delta) | |
CL2008000121A1 (es) | Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta. | |
CL2013002811A1 (es) | Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion. |